UK markets closed
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • FTSE 250

    20,615.59
    -160.16 (-0.77%)
     
  • AIM

    1,173.12
    -10.50 (-0.89%)
     
  • GBP/EUR

    1.1248
    -0.0014 (-0.12%)
     
  • GBP/USD

    1.3585
    -0.0106 (-0.77%)
     
  • BTC-GBP

    26,280.74
    -1,373.94 (-4.97%)
     
  • CMC Crypto 200

    682.93
    -52.21 (-7.10%)
     
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • DOW

    30,814.26
    -177.26 (-0.57%)
     
  • CRUDE OIL

    52.15
    -1.42 (-2.65%)
     
  • GOLD FUTURES

    1,825.70
    -25.70 (-1.39%)
     
  • NIKKEI 225

    28,519.18
    -179.08 (-0.62%)
     
  • HANG SENG

    28,573.86
    +77.00 (+0.27%)
     
  • DAX

    13,787.73
    -200.97 (-1.44%)
     
  • CAC 40

    5,611.69
    -69.45 (-1.22%)
     

8,242 Orion Corporation A shares converted into B shares

Orion Oyj
·1-min read

ORION CORPORATION STOCK EXCHANGE RELEASE 18 DECEMBER 2020 at 9.10 EET

8,242 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 8,242 A shares have been converted into 8,242 B shares. The conversion has been entered into the Trade Register on 18 December 2020.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 35,122,793 A shares and 106,011,485 B shares. The number of votes of the company's shares is after the conversion 808,467,345.

Orion Corporation

Jari Karlson
CFO

Olli Huotari
SVP, Corporate Functions


Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled pulmonary medication under Easyhaler® device portfolio. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.